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In this issue of Blood, Isakson et al identify autophagy as a new pathway for therapyinduced PML/RARA degradation, a critical determinant for leukemia eradication.
A cute promyelocytic leukemia (APL) is characterized by the t(15;17) chromosomal translocation that fuses the promyelocytic leukemia (PML) gene with that of retinoic acid receptor A (RARA). This rare acute myeloid leukemia exhibits a differentiation block at the promyelocytic stage of granulocytic maturation, hence its name. APL is a paradigm for oncoprotein-targeted therapy. Indeed, at the molecular level, the 2 clinically active therapies, all trans-retinoic acid (ATRA) and As 2 O 3 , both induce the degradation of the PML/RARA fusion protein.
ATRA degrades both RARA and PML/ RARA, while conversely As 2 O 3 degrades both PML and PML/RARA. Thus, these 2 serendipitously discovered agents actually target each of the 2 constitutive moieties of the oncoprotein (see figure) . Several lines of evidence, among which is the synergistic effect of the ATRA/As 2 O 3 combination for APL eradication in mice and man, have strongly implicated PML/RARA degradation in disease clearance. [1] [2] [3] PML/RARA is a transcriptional repressor that binds both RARA response elements and de novo DNA sequences, resulting in dominant-negative and gain-of-function properties. Pharmacologic ATRA concentrations release PML/RARA-mediated transcriptional repression and induce differentiation. PML/RARA also disrupts structures formed by the normal PML protein, PML nuclear bodies. These enigmatic domains have been repeatedly implicated in control of cell death or self-renewal of normal or leukemia stem cells. 4 Treatment-induced PML/RARA degradation reverses these effects, allowing differentiation and loss of clonogenic activity, as shown by transplantation studies in mice, culminating in APL eradication. 2, 3, 5 Previous studies had identified 3 distinct pathways for therapy-induced PML/RARA degradation. The first one is cleavage of the PML moiety of PML/RARA by proteases activated by ATRA-induced differentiation. 6 A second ATRA-initiated catabolic pathway activates direct proteasome-dependent degradation of DNA-bound, hormone-activated RARA or PML/RARA, 7 a feedback mechanism conserved for all nuclear receptors. Finally, As 2 O 3 targets the PML part of the fusion protein and specifically induces a SUMOdependent ubiquitin-mediated degradation process that was recently elucidated at the biochemical and cellular level. 8 In the accompanying report, 9 a fourth pathway, autophagy, was conclusively implicated in both ATRA-and As 2 O 3 -mediated PML/RARA degradation. The authors first demonstrate that PML/RARA is a highly insoluble protein. Misfolded proteins form aggregates that are often cleared by autophagy within the cytoplasm. The authors thus examine the consequence of activation or inhibition of autophagy on PML/RARA stability and observe that this process regulates basal PML/RARA protein levels. Importantly, both ATRA and As 2 O 3 activate autophagy and PML/RARA is detected in cytoplasmic autophagic vesicles after treatment with these agents. Functionally, activation of autophagy by the mammalian target of rapamycin (mTOR) inhibitor triggers PML/RARA destabilization in the NB4 APL cell line, resulting in enhanced ATRA-induced differentiation. Conversely, the autophagy inhibitor BafA impedes treatment-induced PML/ RARA degradation and biologic response.
These results are important in several respects. They identify a novel cytoplasmic PML/RARA catabolic pathway and explain why some studies had observed PML/RARA in the cytoplasm. Other oncogenic fusion proteins may share similar features of poor solubility and may be targets of autophagy. This study also raises interesting questions as to the possible links between autophagy and PML, which is highly stress-sensitive and may also assemble into cytoplasmic bodies. 4 Finally, PML suppresses mTOR activity, 10 a key inhibitor of the autophagic process. Then, release of PML from PML/RARA by ATRA or As 2 O 3 treatment induces a self-perpetuating cycle accelerating PML/RARA degradation. The latter could be implicated in enhanced differentiation, as suggested in the Isakson study, but also in loss of self-renewal of APL clonogenic progenitors. Thus, modulation of autophagy in APL could have important therapeutic consequences.
Conflict-of-interest disclosure: The authors declare no competing financial interests. ■ Most antithrombotic approaches target prevention rather than the more clinically relevant issue of resolution of an existing thrombus. In this issue of Blood, Zhang and colleagues 1 describe a novel and effective therapeutic strategy for clearance of preexisting arterial thrombus in murine models of ischemic stroke.
A rterial thrombosis is initiated by platelets adhering to the damaged vessel wall. These adherent platelets become activated, leading to activation of the platelet integrin glycoprotein (GP) IIb-IIIa (␣ IIb ␤ 3 ), which in binding fibrinogen and von Willebrand factor allows formation of a platelet aggregate or mural thrombus. At the same time, the damaged vessel wall and the activated platelet surface provide an acceleration of localized coagulation leading to thrombus stabilization by fibrin. 2 Thrombosis precipitating ischemic stroke is a major cause of morbidity and death. The capacity to limit brain infarct formation and resultant permanent neurologic damage requires resolution of the arterial thrombus, ideally within a narrow therapeutic window of up to 4 hours postocclusion. Clinical studies with GPIIb-IIIa receptor antagonists 3 or other profibrinolytic approaches 4 are not optimal and are typically associated with a high incidence of bleeding. Current treatment of acute ischemic stroke with tissue plasminogen activator shows best utility within 4.5 hours of occlusion and can also be associated with clinically significant bleeding, 5 highlighting the pressing need for better and safer therapeutic approaches.
Zhang and colleagues have previously described a unique antiplatelet autoantibody in patients with HIV-or hepatitis C-related thrombocytopenia that recognizes the sequence GPIIIa49-66 and induces complement-independent platelet lysis by generation of reactive oxygen species and peroxide after platelet-reduced nicotinamide adenine dinucleotide phosphate oxidase activation. 6, 7 Subsequently, they identified a human single-chain fragment variable region (scFv) antibody that recognized GPIIIa49-66 (A11), with similar functional properties to the patient autoantibody in that it preferentially bound to activated platelets and could also lyse arterial thrombus in vitro. In the current 
